Logo

ARTL

Artelo Biosciences, Inc.

ARTL

Artelo Biosciences, Inc. • NASDAQ
$1.74 ▲ 4.82% (+0.08)
Market Cap $3.51 M
52w High $28.60
52w Low $1.52
Dividend Yield 0%
P/E -0.09
Volume 22.47K
Outstanding Shares 2.02M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $3.15M ▲ $-3.221M ▼ 0% $-5.612 ▼ $-3.149M ▼
Q1-2025 $0 $2.379M ▼ $-2.372M ▲ 0% $-0.72 ▲ $-2.379M ▲
Q4-2024 $0 $3.812M ▲ $-3.778M ▼ 0% $-7 ▼ $-3.812M ▼
Q3-2024 $0 $1.195M ▼ $-1.132M ▲ 0% $-0.35 ▲ $-1.132M ▲
Q2-2024 $0 $2.512M $-2.433M 0% $-0.75 $-2.433M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $2.066M ▲ $4.357M ▲ $5.763M ▲ $-1.406M ▼
Q1-2025 $746K ▼ $3.515M ▼ $2.863M ▲ $652K ▼
Q4-2024 $2.338M ▼ $4.698M ▼ $1.841M ▲ $2.857M ▼
Q3-2024 $4.857M ▼ $7.136M ▼ $775K ▼ $6.361M ▼
Q2-2024 $5.602M $8.326M $1.027M $7.299M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-3.994M ▼ $-488K ▲ $-399K ▼ $3.068M ▲ $-3.653M ▼ $-488K ▲
Q1-2025 $-2.372M ▲ $-1.597M ▲ $0 ▼ $0 ▼ $-1.592M ▲ $-1.597M ▲
Q4-2024 $-3.778M ▼ $-2.567M ▼ $500K ▼ $57K ▲ $-2.019M ▼ $-2.567M ▼
Q3-2024 $-2.281M ▲ $-858.428K ▼ $4.338M ▲ $794.501 ▲ $3.476M ▲ $-1.974M ▼
Q2-2024 $-2.433M $-2.063K $1.75K $0 $-314 $-2.063K

Five-Year Company Overview

Income Statement

Income Statement Artelo is still a pure research-stage biotech with no product sales, so its income statement is almost entirely research and operating costs. Those costs have produced steady losses each year, which is typical for an early-stage drug developer. Losses per share have narrowed over time, but that appears driven more by capital structure changes and share consolidations than by any major shift in the underlying business. Overall, the company is still firmly in the spending phase, investing in trials and development without any offsetting revenue yet.

Balance Sheet

Balance Sheet The balance sheet is very small and almost entirely equity-funded, with no meaningful debt, which reduces financial leverage risk but also highlights limited resources. Cash and total assets have trended down, indicating that the company has been drawing on its cash reserves to fund operations. Equity has followed the same pattern, reflecting cumulative losses. Multiple reverse stock splits in recent years signal ongoing efforts to manage share count and maintain listing standards, and they often go hand-in-hand with capital raises and dilution over time.

Cash Flow

Cash Flow Cash flows show a consistent, modest cash burn from operating activities, with essentially no spending on physical assets, which fits a lean, research-heavy biotech model. All meaningful cash outflow is tied to running the business and clinical programs, not to factories or equipment. With no incoming cash from products and no obvious internal cash generation, the company’s ability to keep funding operations depends heavily on access to new capital or partnership funding. The key financial question is always how long the current cash can sustain the pipeline and when additional funding will be needed.

Competitive Edge

Competitive Edge Artelo operates in highly specialized niches: cancer-related weight and muscle loss, chemotherapy-induced nerve pain, and anxiety and PTSD. These are areas with serious unmet medical needs and few or no approved treatments, which gives the company a potentially favorable competitive lane if its drugs succeed. Its lead programs are differentiated by novel mechanisms, especially around the endocannabinoid system and lipid signaling, and by attempts to reduce side effects seen with older cannabinoid-based treatments. However, the broader fields of cancer care, pain, and neuropsychiatry are crowded with both small biotechs and large pharmaceutical companies, so Artelo’s position ultimately depends on how strong and reproducible its clinical data are, and whether it can secure larger partners for late-stage development and commercialization.

Innovation and R&D

Innovation and R&D Innovation is the company’s central strength. It has three distinct platforms: a dual-acting drug for cancer cachexia aiming to boost appetite and preserve muscle while minimizing psychoactive effects; a first-in-class inhibitor for neuropathic pain that targets a novel fatty acid binding protein pathway; and a patented CBD-based cocrystal designed to improve consistency and effectiveness in treating PTSD and anxiety. This gives Artelo multiple shots on goal, anchored by unique mechanisms and intellectual property protection, especially for its CBD cocrystal. Early and interim clinical data in some programs look encouraging, but all assets are still in the clinical development phase, which carries high scientific, regulatory, and timing uncertainty. Progress depends on successfully moving each program through later-stage trials and converting scientific promise into clear clinical benefit.

Summary

Artelo is a small, clinical-stage biotech that is still pre-revenue and consistently loss-making, funding research into a handful of differentiated drug candidates. Its financial profile is typical for an early developer: a thin, equity-based balance sheet, no debt, ongoing cash burn, and likely reliance on external financing or partnerships. Strategically, the company is focused on underserved areas with limited existing treatments, supported by novel mechanisms and patent protection that could create a defensible niche if trials succeed. The main opportunities lie in successful clinical readouts, partnering deals, and expansion of its platforms to additional diseases. The main risks are the usual ones for a company at this stage: clinical setbacks, regulatory hurdles, financing needs, and competition from better-funded peers. Overall, the story is driven far more by scientific and development milestones than by current financial performance.

NEWS

November 12, 2025 · 8:00 AM UTC

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Read more

November 4, 2025 · 8:30 AM UTC

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Read more

October 27, 2025 · 8:00 AM UTC

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Read more

October 15, 2025 · 9:15 AM UTC

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Read more

October 1, 2025 · 4:05 PM UTC

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Read more